摘要
目的对比分析血液透析和腹膜透析治疗终末期肾病的临床效果,为临床治疗终末期肾病提供参考依据。方法选择我院2010年1月1日~2011年1月1日期间收治的终末期肾病患者80例作为本次研究的实验组和对照组,参与本次研究的80例患者均采取信封抽取法进行分组,每组40例,对照组40例采取血液透析治疗,实验组40例采取腹膜透析治疗,并在治疗结束后,比较两组的治疗效果。结果实验组的血浆白蛋白水平高于对照组（P〈0.05）;实验组的心功能不全事件、出血事件、脑梗死发生率均低于对照组（P〈0.05）;实验组的1年生存率为75.00%（30/40）,5年生存率为52.50%（21/40）,对照组的1年生存率为60.00%（24/40）,5年生存率为40.00%（16/40）,差异具有统计学意义（P〈0.05）。结论腹膜透析治疗终末期肾病具有显著疗效,可有效提高患者的生存率和减少不良事件,值得在临床实践中应用推广。
Objective To provide reference for clinical treatment of end stage renal disease by comparing and analyzing the clinical effect of hemodialysis and peritoneal dialysis in the treatment of end stage renal disease. Methods 80 cases of eventually end stage renal disease patients cured in our hospital from January 1, 2010 to January 1, 2011 were divided into the experimental group and the control group by envelope extraction method, 40 cases in each. Patients in the control group were treated with hemodialysis, and patients in the experimental group were treated with peritoneal dialysis treatment. And after the end of treatment, the treatment effect of the two groups were compared and analyzed. Results The level of serum albumin of the experimental group was higher than that of the control group（P 0.05）. The heart failure events, bleeding events, cerebral infarction incidence of the experimental group were lower than those of the control group（P 0.05）. The survival rate at 1 year and 5 year survival rates of the experimental group were75.00%（30/40） and 52.50%（21/40）, 1 year survival rate of the control group and 5 years survival rates were 60.00%（24/40） and 40.00%（24/40）. The differences were statistically significant（P 0.05）. Conclusion Peritoneal dialysis treatment of end stage renal disease had a significant effect, could effectively improve the survival rate of patients and reduce unsafe events, it was worthy to be popularized in clinical practice.
出处
《中国医药科学》
2016年第12期169-171,共3页
China Medicine And Pharmacy
关键词
血液透析
腹膜透析
终末期
肾病
Hemodialysis
Peritoneal dialysis
End stage
Renal disease
